The Nigeria Biotech startup,Syndicate Bio becomes the first African Startups Lab to advance cancer diagnosis with SOPHiA GENETICS

The Nigeria Biotech startup,Syndicate Bio becomes the first African Startups Lab to advance cancer diagnosis with SOPHiA GENETICS. A groundbreaking partnership between Nigerian biotech startup Syndicate Bio and SOPHiA GENETICS, a leader in cloud-based data-driven medicine, marks a significant leap forward for cancer care in Africa.

This collaboration positions Syndicate Bio as the first laboratory on the continent to offer comprehensive genomic profiling and liquid biopsy services, previously unavailable to many patients.

[DOWNLOAD OUR MAGAZINE]

• ALVIN RUME OPHI: INSIDE THE MIND OF A CRYPTO ANALYST 
• DONJAZZY: MAKING MILLIONS WITH CRYPTO IN 10 MINUTES
• JUDE OZINEGBE: INSPIRING NEXT GENERATION DIGITAL ECONOMY
• Herbert Wigwe: Everything You Need to Know [WIGWE ODYSSEY]

Democratizing Genetic Testing and Empowering Healthcare Providers

Leveraging SOPHiA GENETICS’ expertise in cloud-based healthcare solutions, Syndicate Bio aims to democratize access to genetic testing across Africa. This partnership empowers healthcare providers with advanced diagnostic tools, including:

• Non-invasive cancer analysis: Liquid biopsies, a minimally invasive blood test, can detect cancer cells or circulating tumor DNA, aiding in early detection and personalized treatment plans.
• Predictive genetic testing: Identifying genetic mutations associated with increased cancer risk allows for preventive measures and early intervention.
• Precision medicine: Advanced genomic profiling helps tailor treatments to individual patients based on their specific cancer characteristics, leading to potentially more effective therapies.

Addressing a Critical Need in Africa

The urgency of this initiative is underscored by the staggering statistics:

• 1.1 million new cancer cases diagnosed annually in Africa (World Health Organization).
• Approximately 700,000 cancer-related deaths each year in Africa (WHO).
• Projected cancer deaths to reach 1 million annually by 2030 without significant interventions (WHO).

Syndicate Bio’s laboratory bridges critical gaps in diagnostic capabilities, particularly for underserved communities and individuals who previously had to seek testing outside Africa.

A Collaboration with Global Impact

Dr. Abasi Ene-Obong, Founder of Syndicate Bio, emphasizes the far-reaching potential of this partnership: “Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, thereby enhancing patient outcomes continent-wide.”

The impact extends beyond immediate clinical benefits. By leveraging data insights from the collaboration, the aim is to:

• Drive innovation: Advancements in cancer research and drug discovery can be spurred by the vast datasets generated.
• Accelerate drug discovery: Identifying potential drug targets can lead to the development of new and more effective cancer treatments.
• Improve global health outcomes: The knowledge gained can benefit not just Africa but contribute to advancements in healthcare worldwide.

CLICK HERE TO READ ABOUT OUR UPDATES ON EAST AFRICA

Building on a Foundation of Pioneering Research

Syndicate Bio’s commitment to innovation goes beyond this recent partnership. In October 2023, they solidified their dedication to genomic research by signing a Memorandum of Understanding (MoU) with the Nigerian Institute of Medical Research (NIMR). This collaboration focuses on:

• Transformative studies: Joint research initiatives addressing both infectious and non-infectious diseases prevalent in Nigeria.
• Ethical oversight: NIMR’s expertise and infrastructure ensure adherence to ethical research practices, safeguarding patient well-being.
• Tailored healthcare solutions: Leveraging NIMR’s resources allows for the development of healthcare solutions specifically addressing the needs of the Nigerian population.

A Brighter Future for Cancer Care in Africa

The partnership between Syndicate Bio and SOPHiA GENETICS marks a new era for cancer care in Africa. By offering advanced diagnostic tools, empowering healthcare providers, and driving innovation, this collaboration offers hope for a future with earlier diagnoses, more effective treatments, and improved patient outcomes across the continent.